A 51-year-old man presented with worsening fatigue on exertion and pallor with an ECOG performance score of 1. He eventually received a diagnosis of stage II standard-risk multiple myeloma after testing and examination.
A patient with metastatic castration-resistant prostate cancer received external beam radiation therapy and androgen deprivation therapy became asymptomatic, then presented with hip pain and urinary frequency 6 months later.
During separate virtual live events, Matthew A. Gubens, MD, MS, and Rodolfo
Bordoni, MD, discussed the CASPIAN trial of durvalumab plus platinum therapy and etoposide and whether the participants have used this regimen in patients with small cell lung cancer.
David I. Quinn, MD, MBBS, PhD and other oncologists, discussed disease management and the option of using an osteoclast-targeting agent for a 75-year-old man with metastatic castration-resistant prostate cancer.